CIPLACipla

₹1503.3-0.54%

Market Cap

₹1,21,298.96 Cr

Stock P/E

22.29

ROCE

23.64%

ROE

18.34%

Book Value

₹407.53

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

Cipla Acquires 100% Stake in Inzpera Healthsciences

Strategic Initiatives

1 day ago

Cipla Announces Leadership Transition Ahead of 2026

Management Change

5 days ago

Shareholding

Holdings

Distribution

Promoter

Foreign Investors

Domestic Investors

Public

From Last Concall

POSITIVES

•
Revenue resilience with healthy EBITDA margin and strong quarterly topline.
•
India growth momentum visible with One India topping INR3,000 crores and 6% YoY growth.

NEGATIVES

•
Revlimid exposure could cause near-term revenue phasing as pricing erodes.
•
U.S. FDA regulatory risk flagged by VAL/VAI classifications for facilities.

Peers Summary

No Peers Data

Peer comparison data is not available for this stock.

Explore

Watchlists

Command Palette